



**Universiteit  
Leiden**  
The Netherlands

## **Genetic studies in rheumatoid arthritis**

Kurreeman, F.

### **Citation**

Kurreeman, F. (2009, November 4). *Genetic studies in rheumatoid arthritis*.  
Retrieved from <https://hdl.handle.net/1887/14323>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/14323>

**Note:** To cite this publication please use the final published version (if applicable).

## **Chapter 16**

### **Association of *IL2RA* and *IL2RB* with rheumatoid arthritis - a replication study in a Dutch population**

F.A.S. Kurreeman

N.A. Daha

M. Chang

J.J. Catanese

A.B. Begovich

T.W.J. Huizinga

R.E.M. Toes

Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.  
Celera, Alameda, CA, USA.

*Manuscript in press at Ann. Rheum Dis.*

Rheumatoid arthritis is an autoimmune-disease with a prevalence of ~1% world wide. The etiology of RA is largely unknown; however it is thought that both genetic as well as environmental factors play a role in the pathogenesis of the disease. Genome wide association studies (GWAS) as well as candidate gene approaches have led to the association of a number of genetic susceptibility loci (1-7). The Wellcome Trust case-control consortium (WTCCC), the first GWAS in RA, identified a number of loci reaching genome-wide significance including the HLA-region and the *PTPN22* gene (5). To identify new genetic risk factors, Thomson *et al.* investigated whether tier 2 single nucleotide polymorphisms (SNPs) ( $P=1 \times 10^{-5}$ - $1 \times 10^{-7}$ ) in the WTCCC-GWAS showed association with RA in an independent validation study of 5063 patients and 3849 healthy controls(8). Of the nine loci investigated, significant association with rs6920220 in the *TNFAIP3-OLIG3* region was identified (OR 1.23, 95%CI-1.15-1.33,  $P=1.1 \times 10^{-8}$ ). Association of RA with this region was independently identified by Plenge and coworkers (2) and a recent meta-analysis of GWAS data from three independent case-control populations of European descent confirmed these results(3). To further investigate these tier 2 SNPs, the control group of the validation study was enlarged from 3849 to 11487 individuals by including non-RA disease groups consisting of bipolar disorder, Type 2 Diabetes, hypertension and coronary artery disease(9). In addition to association with rs6920220, other statistically significant SNPs surfaced, located in *MMEL1*, *IL2RA* and *IL2RB*. Furthermore, investigation of forty-nine tier 3 loci ( $P=1 \times 10^{-4}$ - $1 \times 10^{-5}$ ) from the original WTCCC-GWAS, identified significant RA-associated SNPs located in *PRKCCQ* and *KIF5A* (8). Three of these regions, encoding *MMEL1*, *KIF5A* and *PRKCCQ*, were also identified in a large independent study of RA samples of European descent (3), suggesting that these regions harbor true RA susceptibility loci.

In the present study we addressed the contribution of the two IL-2-pathway SNPs, specifically rs743777 located in *IL2RB* and rs2104286 in *IL2RA*, to RA risk in an independent Dutch case-control study. This is of relevance, not only because additional replication would strengthen the putative contribution of IL-2-receptor-positive cells to RA, but also because only a trend towards association for the *IL2RA* SNP, was observed after correction for multiple testing using the Bonferroni-method ( $P < 0.0056$ ). 616 Dutch patients and 545 healthy, ethnically and geographically matched controls were genotyped by allele specific kinetic PCR as previously described(10). In this study, significant association with RA for both rs743777 and rs2104286 was observed (OR 1.26, 95%CI 1.06-1.50,  $P=0.009$ ; OR 0.81, 95%CI 0.67-0.98,  $P=0.026$  respectively) (Table1). Combining the data from our study with the UK data strengthened the evidence for association (rs743444: OR 1.12, 95%CI 1.06-1.18,  $P=8.6 \times 10^{-6}$ ; rs2104286: OR 0.92, 95%CI 0.87-0.97,  $P=1.2 \times 10^{-3}$ ) (Table1). To bypass the phenomenon of the 'winners curse', in which effect sizes are often overestimated in the original study(13), we opted to analyze the data without the original WTCCC data to provide an estimate of the most likely effect size. In conclusion, this study provides additional evidence for the association of *IL2RB* and *IL2RA* with RA by independent replication in a Dutch population, underlining the importance of the IL-2 pathway in RA. Recently the *IL2RA* region was also found to be associated with other autoimmune diseases(11;12), specifically multiple sclerosis and type 1 diabetes, which suggests a possible common functional pathway.

	N	cases			MAF	N	controls			MAF	OR(95%CI)	P-value	HW-test
		11	12	22			11	12	22				
<b>IL2RB rs743777</b>													
This study	616	76(0.12)	288(0.47)	252(0.41)	0.36	544	58(0.11)	217(0.40)	269(0.49)	0.31	1.26(1.06-1.50)	0.009	0.37
Validation study UK	4680	532(0.11)	2031(0.43)	2117(0.45)	0.33	11200	1040(0.09)	4832(0.43)	5328(0.48)	0.31	1.11(1.05-1.17)	0.0001	0.50
<b>Combined</b>											<b>1.12(1.06-1.18)</b>	<b>8.6*10<sup>-6</sup></b>	
<b>IL2RA rs2104286</b>													
This study	616	36(0.06)	226(0.37)	354(0.57)	0.24	545	54(0.10)	200(0.37)	291(0.53)	0.29	0.81(0.67-0.98)	0.026	0.10
Validation study UK	4660	312(0.07)	1740(0.37)	2608(0.56)	0.24	11260	790(0.07)	4464(0.40)	6006(0.53)	0.28	0.93(0.88-0.98)	0.007	0.59
<b>Combined</b>											<b>0.92(0.87-0.97)</b>	<b>0.0012</b>	

**Table 1.** Analysis of rs743777 and rs2104286 with RA in two populations of northern-European descent. Allele frequency data of RA cases versus controls was compared using a fixed effects (Mantel-Haenszel) meta-analysis. No significant heterogeneity or deviation from Hardy-Weinberg (HW) equilibrium was observed among the studies.

**Reference List**

- (1) Kurreeman FA, Padyukov L, Marques RB, Schrodi SJ, Seddighzadeh M, Stoeken-Rijsbergen G et al. A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis. *PLoS Med* 2007; 4(9):e278.
- (2) Plenge RM, Cotsapas C, Davies L, Price AL, de Bakker PI, Maller J et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. *Nat Genet* 2007; 39(12):1477-82.3
- (3) Raychaudhuri S, Remmers EF, Lee AT, Hackett R, Guiducci C, Burt NP et al. Common variants at CD40 and other loci confer risk of rheumatoid arthritis. *Nat Genet* 2008; 40(10):1216-23.
- (4) Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. *N Engl J Med* 2007; 357(10):977-86.
- (5) The Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* 2007; 447(7145):661-78.
- (6) Zhernakova A, Alizadeh BZ, Bevova M, van Leeuwen MA, Coenen MJ, Franke B et al. Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases. *Am J Hum Genet* 2007; 81(6):1284-8.
- (7) Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC et al. Amisense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. *Am J Hum Genet* 2004; 75(2):330-7.
- (8) Thomson W, Barton A, Ke X, Eyre S, Hinks A, Bowes J et al. Rheumatoid arthritis association at 6q23. *Nat Genet* 2007; 39(12):1431-3.
- (9) Barton A, Thomson W, Ke X, Eyre S, Hinks A, Bowes J et al. Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13. *Nat Genet* 2008; 40(10):1156-9.
- (10) Chang M, Rowland CM, Garcia VE, Schrodi SJ, Catanese JJ, van der Helm-van Mil AH et al. A large-scale rheumatoid arthritis genetic study identifies association at chromosome 9q33.2. *PLoS Genet* 2008; 4(6):e1000107.
- (11) Vella A, Cooper JD, Lowe CE, Walker N, Nutland S, Widmer B et al. Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. *Am J Hum Genet* 2005; 76(5):773-9.
- (12) Matesanz F, Fernandez O, Alcina A. Genomewide study of multiple sclerosis. *N Engl J Med* 2007; 357(21):2200-1.
- (13) Kraft P. Curses--winner's and otherwise--in genetic epidemiology. *Epidemiology* 2008; 19(5):649-51.